Management of Acute Lung Injury: Palmitoylethanolamide as a New Approach

Peritore AF, D'Amico R, Siracusa R, Cordaro M, Fusco R, Gugliandolo E, Genovese T, Crupi R, Di Paola R, Cuzzocrea S, Impellizzeri D. Int J Mol Sci. 2021 May 24;22(11):5533.

Laboratory studyOther animals

Design

Laboratory study

Subjects

Mice given intratracheal lipopolysaccharide (LPS) to induce acute lung injury

Dose used in the study

Ultramicronised PEA (um-PEA); exact dose and administration route not stated in the abstract

Duration

Not stated in the abstract

What was measured

Lung histopathology, wet/dry weight ratio, myeloperoxidase (neutrophil marker), immune cell counts, mast cell degranulation, cytokines (IL-6, IL-1beta, TNF-alpha, IL-18), and NF-kappa-B/MAPK (ERK1/2, JNK, p38) signalling

What the authors reported

um-PEA reduced lung tissue damage, the wet/dry weight ratio, myeloperoxidase activity, immune cell infiltration and mast cell degranulation after LPS challenge, and lowered IL-6, IL-1beta, TNF-alpha and IL-18 release while reducing NF-kappa-B and MAPK (ERK1/2, JNK, p38) activation.

Limits of this study

A mouse model of LPS-induced lung injury; it cannot show effect in people. Salvatore Cuzzocrea is a co-inventor on PEA-related patents held with Epitech Group, described as unrelated to this study.

Source

PubMed 34073872 · doi:10.3390/ijms22115533

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.